According to data from the Kazakh Ministry of Health, the share of domestic medicine manufacturers has reached 39.8 per cent, according to
Kazinform, a partner of TV BRICS. This growth is attributed to a sustained state policy of support for the pharmaceutical sector and the implementation of regulatory measures by the competent authorities.
Deputy Health Minister Timur Muratov noted during a field session of the Mazhilis’ Committee on Social and Cultural Development that these results have been made possible by the transparency provided by the medicines labelling and traceability system, which allows for a precise understanding of the structure of the pharmaceutical market.
According to the authorities, since the end of 2025, seven major investment agreements have been signed in the pharmaceutical sector, worth approximately US$756 million. These projects envisage the creation of around 500 new types of medicines and medical products, as well as the creation of over a thousand jobs.
The Ministry of Health emphasised that strengthening the national pharmaceutical industry is key to the country’s health security, the stability of the healthcare system and improving the population’s access to quality medicines.
Furthermore, it was noted that the implementation of the medicines’ labelling system has already generated additional revenue of approximately US$50.4 million for the national budget.
In this context, the BRICS countries are also showing growing development in the pharmaceutical sector, with diverse strategies that strengthen their position in the sector globally.
According to
IANS, a partner of TV BRICS, India’s pharmaceutical sector has established itself as one of the most important in the world, ranking third globally by volume and eleventh by value. The country has more than 3,000 companies and over 10,500 production units and has specialised in the manufacture of generic medicines, which account for around 20 per cent of the global supply.
Furthermore, India is a key player in vaccine production, supplying a large part of the demand from international organisations such as UNICEF and the WHO, which reinforces its role in global health supply chains.
In Egypt, Olga Butranova, Candidate of Medical Sciences and Associate Professor at the Department of General and Clinical Pharmacology of the Peoples’ Friendship University of Russia (RUDN) Medical Institute, noted in an exclusive interview with TV BRICS that the country’s pharmaceutical sector has become increasingly self-sufficient. According to her, this progress has been driven by the creation of industrial clusters bringing together local and foreign manufacturers. This process has fostered a high degree of localisation in production, reaching approximately 91 per cent, driving the development of generic medicines, which account for around 70 per cent of the domestic market.
Egypt has around 180 pharmaceutical factories and more than 80,000 pharmacies, which has significantly strengthened its domestic production capacity. This growth has also enabled progress in the manufacture of high-tech medicines, such as vaccines and monoclonal antibodies, and consolidating the country’s position as a key player in regional pharmaceutical production.
In Russia, pharmaceutical development has focused on scientific innovation and sustainability. Researchers have made progress in the synthesis of pharmaceutical compounds using cleaner and more efficient methods, in line with the principles of green chemistry, as
reported by the Ministry of Science and Higher Education of the Russian Federation.
These new techniques enable the production of bioactive molecules without toxic solvents or catalysts, reducing the environmental impact and simplifying manufacturing processes. This type of research opens up new possibilities for the development of drugs to treat diseases such as cancer, fungal and bacterial infections, reinforcing the role of Russian science in the global pharmaceutical industry.